{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:02:30Z","timestamp":1792544550623,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jaad.2019.05.022","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T01:35:34Z","timestamp":1557711334000},"page":"702-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa"],"prefix":"10.1016","volume":"81","author":[{"given":"Ashley N.","family":"Oskardmay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alex","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2019.05.022_bib1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0625.2008.00712_1.x","article-title":"What causes hidradenitis suppurativa?","volume":"17","author":"Ralf Paus","year":"2008","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.022_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"issue":"5 Suppl 1","key":"10.1016\/j.jaad.2019.05.022_bib3","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jaad.2015.07.055","article-title":"Systemic associations of hidradenitis suppurativa","volume":"73","author":"Kohorst","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.022_bib4","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-\u03b2","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.022_bib5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.05.022_bib6","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.022_bib7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor-\u03b1 in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-\u03b1 agents?","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.022_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.022_bib9","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bjd.12713","article-title":"Four-weekly infliximab in the treatment of severe hidradenitis suppurativa","volume":"170","author":"Moriarty","year":"2014","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.022_bib10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/09546634.2012.683767","article-title":"Long-term efficacy of infliximab in hidradenitis suppurativa","volume":"23","author":"Paradela","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.022_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/09546634.2011.571657","article-title":"Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa","volume":"23","author":"van Rappard","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.022_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2133.2012.10807.x","article-title":"Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions","volume":"167","author":"Van Rappard","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.022_bib13","author":"Thompson"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.022_bib14","first-page":"373","article-title":"Use of biological treatments in patients with hidradenitis suppurativa","volume":"152","author":"Martin-Ezquerra","year":"2017","journal-title":"G Ital Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.022_bib15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaad.2016.08.036","article-title":"Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa","volume":"76","author":"Montaudi\u00e9","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5 Suppl 1","key":"10.1016\/j.jaad.2019.05.022_bib16","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jaad.2015.07.053","article-title":"Treatment of hidradenitis suppurativa with biologic medications","volume":"73","author":"Lee","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.022_bib17","unstructured":"Horsham P. Remicade (infliximab) [prescribing information]. November 2013. Horsham, PA: Janssen Biotech Inc."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219307856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219307856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:51:18Z","timestamp":1759272678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219307856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0190962219307856"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.022","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}